



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/814,527	03/30/2004	Alpern Robert	RLY 04021.101	6886
58415 7590 11/25/2009 SENNIGER POWERS LLP (ILPS) 100 NORTH BROADWAY 17TH FLOOR ST. LOUIS, MO 63102				
EXAMINER				
LEVY, NEIL S				
ART UNIT		PAPER NUMBER		
1615				
NOTIFICATION DATE		DELIVERY MODE		
11/25/2009		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

uspatents@senniger.com

Office Action Summary

Application No.

10/814,527

Applicant(s)

ROBERT ET AL.

Examiner

NEIL LEVY

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 September 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,5-11,13-16,36-49,51,60-76 is/are pending in the application.
- 4a) Of the above claim(s) 3,5-11,45-48 and 51 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,13-15,36-44,49,60-76 is/are rejected.
- 7) ☐ Claim(s) 16 is/are objected to.
- 8) ☒ Claim(s) 1,3,5-11,13-16,36-49,51,60-76 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-846)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 6/10/09
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim3, 5-11, 45-48,51 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species , there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 4/2/07.

Claim Rejections - 35 USC § 112

claims 1, 13-15, 36-44, 49, 60-76 rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for counter ions of NH₄, Ca, H, cross-linked co-polymers and homopolymers at 4mmol/gm as measured in the feces of a human patients, does not reasonably provide enablement for Any of the polymers as now claimed at any level of Na-binding in the claimed syndromes.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. Low binding, by unspecified co-polymers, would result in other cation binding, and of too low binding to be effective in the claimed syndrome human treatments, with potentially adverse overloading of polymers in these conditions.

Specifying homo-polymers and cross-linked of the stated claim 1 and 62 polymers, specifying counter ions, and inserting the claim 49 subject matter would overcome this rejection.

Claim Rejections - 35 USC § 103

Claims 1, 13-15, 36-44, 60 & 61 stand rejected under 35 U.S.C. 103(a) as being unpatentable over MARTANI EP 039453 IN VIEW OF MURUGESAN et al US005846990A & NOTENBOMER EP 0730494

MARTANI utilizes eudrajit polymers with added actives. As they travel through the GI tract, and release active, the carboxylic moieties of the eudrajit polymer would be free to bind Na, at the same positions of the GI tract and to the same degree, as would administration of the instant polymers. However, MARTANI discusses the oral

formulations, but not the disease states. Those are shown by MURUGESAN, with associated drugs, to be administered, orally, in any suitable manner to humans and animals (column 8, lines 38-46), thus, inclusive of bound to polymers taught by MARTANI.

The same moieties are seen on the NOTENBONER polymer, and they do in fact lower sodium ion levels and water in human and animals (column 4, lines 1-9) when applied in food, feed, drinks, or pharmaceutical compositions.

Martani, applicant's arguments notwithstanding shows a laxative, glycerin (examples 2,3) with acrylic acid & polystyrene sulfonate acid resins, for oral

administration to patients in pain, regardless of their disease(p.3, lines 9-18). Since these dosages are oral, they would remove Na as they pass through the G.I. tract, since these are the instant polymers.

MURUGESAN further shows the instant syndromes for which the instant drugs (claim 43) are suitable , & thus treatment regimens of MARTANI would be obvious to incorporate with useful drugs of MURUGESAN (col. 7).

Notenbomer discloses a particle formulation comprising a cation exchange resin with the claimed moiety, able to bind sodium ions (page 3, lines 3-20). Page 3, lines 8-12 teaches that the particles encapsulate the ions and remove them through the GI tract. Page 3, lines 20-34 discloses examples of the cation exchange material such as polyacrylates. Page 4, lines 1-2 teach that the particles of the invention are good for lowering Na, thus supporting administration of these polymers would result in reducing Na load in a patient in need thereof.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize a Na binding polymer to use one of MARATANI modified with MURUGESAN & Notenbomer drugs, in order to provide acceptable application and improve the status of a patient in need thereof.

There is no unobvious and/or unexpected results obtained since the prior art is well aware of the use of cation exchange polymers for enhancement and the use of ingredients for the functionality for which they are known to be used is not a basis for patentability.

Applicant has not provided any objective evidence of criticality, nonobvious or unexpected results that the administration of the particular ingredients' or concentrations provides any greater or different level of prior art expectation as claimed.

Response to Arguments

Applicant's arguments filed 9/24/-09 have been fully considered but they are not persuasive. Applicant refers to support for the enablement rejection,; however, examiner finds the claimed polymers, while able to bind Na, would also bind other cations and as claimed in methods of treating human in terminal conditions could result in unintended consequences. Non-specific polymers and binding capabilities are seen as providing potentially toxic amounts of polymer, with only some in vitro and limited animal data supporting claimed effects and means of Na binding. As to the 103 rejection, the cited legal references are not understood as to their relevance-none are to the treatment of people with the instantly claimed diseases, treated with the instant polymers and drugs, but cited art of the 103 reference is.

However, the suggested amendments would be seen as overcoming the 112 rejections and would be non-obvious over the art of record.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ROBERT A. WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/
Primary Examiner, Art Unit 1615

11/22/09